Current Editions
FDA approved 46 new molecular entities and 10 new biologics in 2025
Regulation
From preclinical therapies to David Liu’s one-time approach, new tools aim to bypass stop codons across a wide range of diseases
Product Development
Good news and optimism will play out alongside continued uncertainty and disruption
Editor's Commentary
With overall M&A activity steady, $1B-plus deals accounted for more than half of all biotech takeouts in 2025
Finance
Koppel shares his expectations for financial markets, dealmaking in 2026
Finance
Product Development
Phase III psoriasis results position envudeucitinib among leading oral therapies as Alumis plans a $175M follow-on
Clinical trial updates for the week of Jan. 5-9
Biotech looks to raise $700M as its ALK7 data stand out and INHBE results track with peers
Emerging Company Profile
By priming the host immune system, Australian biotech aims to stop upper respiratory viruses in their tracks
Data Byte
Decisions include first sublingual epinephrine for allergic reactions
2025 total hit 46, down from 50 in 2024
Year off to a busy start with flurry of deals announced this week
Discovery & Translation
BioCentury’s translational roundup also features methods to profile off-target base edits, turn macrocycles into antibodies, and more
Politics, Policy & Law
Decisions on designating companies, implementation policies will determine law’s impacts
Deals
Pair of NLRP3 programs appear to drive the deal, with potential in pericarditis, Parkinson’s and obesity-associated cardiometabolic disease
AirNexis formed with $200M round led by Frazier to develop COPD asset to compete with Merck
Plus: Sanofi, Earendil in second tie-up; AbbVie takes option to trispecific from China-based Zelgen; and more
Finance
Megarounds for seven start-ups amid torrent of cash ahead of industry conference
Plus: Basket of follow-ons draws $2B+ for seven companies
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Politics, Policy & Law
Management Tracks
BioCentury ISSN 1097-7201